Respiratory viruses continue to present a burden for the United States, despite the advancement of medical products that effectively prevent or mitigate severe illness, hospitalization, and death. These medical products have received marketing approval and coverage based on benefits to individuals, yet they also likely have population-level benefits that can play an integral role in reducing wide-spread disease transmission. In order to realize the population-level benefits from current products and facilitate the development of next-generation technologies that focus on reducing disease transmission, a systematic, shared framework is needed to promote multistakeholder led deployment. The Duke-Margolis Center for Health Policy has developed a framework for incorporating population benefits into regulatory and reimbursement processes. The framework, along with corresponding regulatory, coverage, and payment policy enacting steps, will be presented in a soon to be released strategy document. On November 14, Duke-Margolis will convene a public workshop focused on a new strategic direction for addressing the burden presented by respiratory viruses. The meeting comes at an important time, with renewed interest in containing the spread of respiratory viruses during the anticipated increase in prevalence in the fall. This event is open to all.